SSR 180711

Drug Profile

SSR 180711

Alternative Names: SR180711; SSR-180711A

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Antidementias; Antipsychotics; Heterocyclic bicyclo compounds; Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Schizophrenia

Most Recent Events

  • 11 Feb 2009 Discontinued - Phase-I for Alzheimer's disease in Europe (PO)
  • 11 Feb 2009 Discontinued - Phase-I for Schizophrenia in Europe (PO)
  • 07 Nov 2007 Pharmacodynamics data from an animal study presented at the 37th Annual Meeting of the Society for Neurosciences (SfN-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top